Literature DB >> 2724303

Thromboxane A2 synthetase inhibitors. 2. Syntheses and activities of tetrahydronaphthalene and indan derivatives.

M Kanao1, Y Watanabe, Y Kimura, J Saegusa, K Yamamoto, H Kanno, N Kanaya, H Kubo, S Ashida, F Ishikawa.   

Abstract

A series of 1-imidazolylalkyl-substituted or 5-thiazolylalkyl-substituted tetrahydronaphthalenecarboxylic acid and indancarboxylic acid derivatives were prepared and tested for the inhibitory activities of thromboxane A2 (TXA2) production in vitro and ex vivo. Most of the compounds showed potent TXA2 synthetase inhibitory activities in vitro and had long duration of inhibition of TXA2 production in rats when orally or intravenously administrated. The imidazole analogues had slightly less potency in vitro than the thiazole analogues, but the activities of the imidazole analogues in ex vivo models were equal or superior to the activities of the thiazole analogues. 6-(1-Imidazolyl-methyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid hydrochloride hemihydrate (47a, DP-1904) was chosen for clinical studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2724303     DOI: 10.1021/jm00126a031

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Pharmacokinetic-pharmacodynamic modelling of DP-1904, a novel thromboxane synthetase inhibitor in rabbits, based on an indirect response model.

Authors:  N X Zheng; H Sato; I Adachi; I Horikoshi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

2.  A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation.

Authors:  D K Agrawal; M Takami; S Ono
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.